http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021212243-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5b831dcc6aac046995e396d8ceab6bf
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43509
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435
filingDate 2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a148e4dad78c37a15ce9866bd4bd05aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_269df6b877f62111b7407fb161ef2813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a9d66eaed386b8f0819cba9d4958a8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9bc378bf3ef7bfb11a8f008fd0a6856
publicationDate 2021-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2021212243-A1
titleOfInvention Avermectin-sensitive and avermectin-insensitive sea lice glucl receptors and uses thereof as therapeutic targets for detecting antiparasitic drugs against caligus rogercresseyi
abstract The present invention relates to the identification of new glutamate-activated chloride channels of Caligus rogercresseyi (CrGluCl), corresponding to CrGluCl-B to CrGluCl-E receptors, according to SEQ ID N°: 2-5, and the use of these channels as therapeutic targets for detecting antiparasitic drugs against Caligus rogercresseyi. The procedure for testing such drugs corresponds to a high-throughput method that comprises: introducing individually into an expression vector, any of SEQ ID N°: 2-5, to express a single CrGluCl channel selected from the CrGluCl-B, CrGluCl-C, CrGluCl-D or CrGluCl-E receptors; or, co-expressing in different vectors, two or more channels in any combination, either of new channels (CrGluCl-B to CrGluCl-E) or together with known channels (CrGluCl-A). Said vectors are introduced into a host cell, which is exposed to a potential-sensing fluorescent dye that allows each test compound to be classified as active or inactive based on the ability of the test compound to cause a change in the fluorescence.
priorityDate 2020-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6473767
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID187
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID992
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393853
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414733
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57507888
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406055
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226414732
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20056419
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226406054
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9812710
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226453498
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226428550
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226428549
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394197
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46936176
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10258
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226415879
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395454
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10690
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID20057258
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226405626
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394044
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441564
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5585
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394880

Total number of triples: 42.